Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Hepatic arterial therapy with oxaliplatin and systemic capecitabine for patients with liver metastases from breast cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{00129a89cdd94aa693e68a30d5186043,
title = "Hepatic arterial therapy with oxaliplatin and systemic capecitabine for patients with liver metastases from breast cancer",
abstract = "OBJECTIVES: Hepatic arterial treatment (HAT) for liver metastases in patients with metastatic breast cancer (MBC) has only been investigated in few studies.MATERIALS AND METHODS: Two phase II trials were initiated simultaneously to evaluate capecitabine in combination with oxaliplatin in patients with MBC and liver metastases. These two trials are reported together. Continuous capecitabine (1300 mg/m2) was combined with oxaliplatin (85 mg/m2) alternating between systemic treatment and HAT followed by degradable starch microspheres with EmboCept{\circledR} S every second week. Four patients participated in a pharmacokinetic analysis of oxaliplatin. Each patient had samples taken when receiving oxaliplatin systemically and as HAT with and without EmboCept{\circledR} S.RESULTS: Totally, 52 patients received HAT: 14 with liver metastases only and 38 patients with additional limited metastatic disease. The patients had previously received a median of 2 (range 0-6) chemotherapeutic regimens for MBC. The response rate was 42.3{\%} (95{\%} confidence interval (CI) 28.7-56.8{\%}) with 7.7{\%} complete and 34.6{\%} partial responses. Median progression free survival was 10.8 months (95{\%} CI 6.9-14.7 months) and median overall survival 27.6 months (95{\%} CI 20.4-34.8 months). The toxicity was moderate with hand-foot syndrome (15.4{\%}), neuropathy (9.6{\%}), fatigue (9.6{\%}), and abdominal pain (9.6{\%}) being the most common grade 3 adverse events. There was no clear difference between systemic blood concentrations of oxaliplatin when given systemic or as HAT.CONCLUSION: HAT oxaliplatin in combination with capecitabine is safe and efficient in patients with MBC. The results are promising with high response rates and a long median progression free and overall survival.",
keywords = "Abdominal Pain/chemically induced, Adenocarcinoma/secondary, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Breast Neoplasms/pathology, Capecitabine/administration & dosage, Chemoembolization, Therapeutic/methods, Fatigue/chemically induced, Female, Hand-Foot Syndrome/etiology, Hepatic Artery, Humans, Liver Neoplasms/secondary, Middle Aged, Oxaliplatin/administration & dosage, Peripheral Nervous System Diseases/chemically induced, Progression-Free Survival",
author = "Lindgaard, {S C} and Brinch, {C M} and Jensen, {B K} and N{\o}rgaard, {H H} and Hermann, {K L} and S Theile and Larsen, {F O} and Jensen, {B V} and H Michelsen and Nelausen, {K M} and Holm, {V H} and L Ekblad and Soerensen, {Peter G} and Nielsen, {D L}",
note = "Copyright {\circledC} 2018 Elsevier Ltd. All rights reserved.",
year = "2019",
month = "2",
doi = "10.1016/j.breast.2018.12.002",
language = "English",
volume = "43",
pages = "113--119",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",

}

RIS

TY - JOUR

T1 - Hepatic arterial therapy with oxaliplatin and systemic capecitabine for patients with liver metastases from breast cancer

AU - Lindgaard, S C

AU - Brinch, C M

AU - Jensen, B K

AU - Nørgaard, H H

AU - Hermann, K L

AU - Theile, S

AU - Larsen, F O

AU - Jensen, B V

AU - Michelsen, H

AU - Nelausen, K M

AU - Holm, V H

AU - Ekblad, L

AU - Soerensen, Peter G

AU - Nielsen, D L

N1 - Copyright © 2018 Elsevier Ltd. All rights reserved.

PY - 2019/2

Y1 - 2019/2

N2 - OBJECTIVES: Hepatic arterial treatment (HAT) for liver metastases in patients with metastatic breast cancer (MBC) has only been investigated in few studies.MATERIALS AND METHODS: Two phase II trials were initiated simultaneously to evaluate capecitabine in combination with oxaliplatin in patients with MBC and liver metastases. These two trials are reported together. Continuous capecitabine (1300 mg/m2) was combined with oxaliplatin (85 mg/m2) alternating between systemic treatment and HAT followed by degradable starch microspheres with EmboCept® S every second week. Four patients participated in a pharmacokinetic analysis of oxaliplatin. Each patient had samples taken when receiving oxaliplatin systemically and as HAT with and without EmboCept® S.RESULTS: Totally, 52 patients received HAT: 14 with liver metastases only and 38 patients with additional limited metastatic disease. The patients had previously received a median of 2 (range 0-6) chemotherapeutic regimens for MBC. The response rate was 42.3% (95% confidence interval (CI) 28.7-56.8%) with 7.7% complete and 34.6% partial responses. Median progression free survival was 10.8 months (95% CI 6.9-14.7 months) and median overall survival 27.6 months (95% CI 20.4-34.8 months). The toxicity was moderate with hand-foot syndrome (15.4%), neuropathy (9.6%), fatigue (9.6%), and abdominal pain (9.6%) being the most common grade 3 adverse events. There was no clear difference between systemic blood concentrations of oxaliplatin when given systemic or as HAT.CONCLUSION: HAT oxaliplatin in combination with capecitabine is safe and efficient in patients with MBC. The results are promising with high response rates and a long median progression free and overall survival.

AB - OBJECTIVES: Hepatic arterial treatment (HAT) for liver metastases in patients with metastatic breast cancer (MBC) has only been investigated in few studies.MATERIALS AND METHODS: Two phase II trials were initiated simultaneously to evaluate capecitabine in combination with oxaliplatin in patients with MBC and liver metastases. These two trials are reported together. Continuous capecitabine (1300 mg/m2) was combined with oxaliplatin (85 mg/m2) alternating between systemic treatment and HAT followed by degradable starch microspheres with EmboCept® S every second week. Four patients participated in a pharmacokinetic analysis of oxaliplatin. Each patient had samples taken when receiving oxaliplatin systemically and as HAT with and without EmboCept® S.RESULTS: Totally, 52 patients received HAT: 14 with liver metastases only and 38 patients with additional limited metastatic disease. The patients had previously received a median of 2 (range 0-6) chemotherapeutic regimens for MBC. The response rate was 42.3% (95% confidence interval (CI) 28.7-56.8%) with 7.7% complete and 34.6% partial responses. Median progression free survival was 10.8 months (95% CI 6.9-14.7 months) and median overall survival 27.6 months (95% CI 20.4-34.8 months). The toxicity was moderate with hand-foot syndrome (15.4%), neuropathy (9.6%), fatigue (9.6%), and abdominal pain (9.6%) being the most common grade 3 adverse events. There was no clear difference between systemic blood concentrations of oxaliplatin when given systemic or as HAT.CONCLUSION: HAT oxaliplatin in combination with capecitabine is safe and efficient in patients with MBC. The results are promising with high response rates and a long median progression free and overall survival.

KW - Abdominal Pain/chemically induced

KW - Adenocarcinoma/secondary

KW - Adult

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Breast Neoplasms/pathology

KW - Capecitabine/administration & dosage

KW - Chemoembolization, Therapeutic/methods

KW - Fatigue/chemically induced

KW - Female

KW - Hand-Foot Syndrome/etiology

KW - Hepatic Artery

KW - Humans

KW - Liver Neoplasms/secondary

KW - Middle Aged

KW - Oxaliplatin/administration & dosage

KW - Peripheral Nervous System Diseases/chemically induced

KW - Progression-Free Survival

U2 - 10.1016/j.breast.2018.12.002

DO - 10.1016/j.breast.2018.12.002

M3 - Journal article

VL - 43

SP - 113

EP - 119

JO - Breast

JF - Breast

SN - 0960-9776

ER -

ID: 59410698